MIRA Pharmaceuticals Announced A Key Development Milestone For Its Novel Topical Formulation Of Ketamir-2 Demonstrated Successful, Dose-proportional Drug Release In A Validated Laboratory Study-8K
Express News | Reported Earlier: 'Texas Lawmakers Take Up Bills To Expedite Access To Psychedelic Therapy' - Marijuana Moment
Is Mira Pharmaceuticals Gaining or Losing Market Support?
BriaCell Therapeutics BCTX Phase 2 Survivor Data; MIRA Pharmaceuticals MIRA Preclinical Ketamine
Sector Update: Health Care Stocks Slide Late Afternoon
Top Midday Gainers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
Express News | Mira Pharmaceuticals Inc - to Initiate Phase Iia Trial in Diabetic Neuropathy Patients by End of 2025
Express News | Mira Pharmaceuticals Inc - Ketamir-2 Shows Significant Reduction in Neuropathic Pain Symptoms - SEC Filing
Express News | EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, With Some Subjects Achieving Complete Symptom Reversal'
Express News | EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Announces Positive Results For Ketamir-2 In Diabetic Neuropathy Animal Model, Says Reinforcing Confidence Ahead Of Phase I Completion
EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study
MIRA Pharmaceuticals | 10-K/A: Annual report (Amendment)
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
Express News | Mira Pharmaceuticals Inc - Phase 1 Study Expected to Complete by Q4 2025 - SEC Filing
MIRA Pharmaceuticals | 10-K: FY2024 Annual Report
Express News | Mira Pharmaceuticals Shares Down 3% After All-Stock Deal for Skny Pharma
Mira Pharmaceuticals Signs LOI to Acquire Skny Pharmaceuticals